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ABSTRACT 
Cancer cells engage in a metabolic program to enhance biosynthesis and support cell 
proliferation. The regulatory properties of pyruvate kinase M2 (PKM2) influence altered glucose 
metabolism in cancer. PKM2 interaction with phosphotyrosine-containing proteins inhibits enzyme 
activity and increases availability of glycolytic metabolites to support cell proliferation. This 
suggests that high pyruvate kinase activity may suppress tumor growth. We show that expression 
of PKM1, the pyruvate kinase isoform with high constitutive activity, or exposure to published small 
molecule PKM2 activators inhibit growth of xenograft tumors. Structural studies reveal that small 
molecule activators bind PKM2 at the subunit interaction interface, a site distinct from that of the 
endogenous activator fructose-1,6-bisphosphate (FBP). However, unlike FBP, binding of activators 
to PKM2 promotes a constitutively active enzyme state that is resistant to inhibition by tyrosine-
phosphorylated proteins. These data support the notion that small molecule activation of PKM2 
can interfere with anabolic metabolism. 
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Cancer cells differ from many normal cells in the way they utilize extracellular nutrients, 
providing a strategy to interfere with tumor growth1,2. The increased cell proliferation that 
characterizes tumor growth imposes an enhanced need for biological building blocks to support 
production of new cells3. To provide for this increased biosynthetic demand, cancer cells exhibit 
higher uptake of nutrients such as glucose. In addition, the metabolic pathways of cancer cells are 
altered to allow production of macromolecules and withstand oxidative stress associated with 
tumorigenesis1,3-6. 
Enhanced glucose uptake is a hallmark of several cancers and is exploited in the clinic as a 
diagnostic tool through PET imaging of the glucose analogue 18F-deoxyglucose (18FDG-PET)7. 
Moreover, in contrast to most normal tissues where much of the glucose is oxidized through the 
TCA cycle in mitochondria, cancer cells preferentially convert glucose to lactate3. The fate of 
glucose inside cells is influenced by the enzymatic properties of the specific glycolytic gene 
products expressed. Expression of the M2 isoform of pyruvate kinase (PKM2) can contribute to the 
characteristic glucose metabolism of tumors and replacement of PKM2 with its splice variant PKM1 
cannot efficiently support biosynthesis and tumor growth8. Thus, pyruvate kinase regulates a step 
in glucose metabolism that can be critical for controlling cell proliferation.  
Pyruvate kinase catalyzes the last step of glycolysis, transferring the phosphate from 
phosphoenolpyruvate (PEP) to adenosine diphosphate (ADP) to yield adenosine triphosphate 
(ATP) and pyruvate. In mammals, two genes encode a total of four pyruvate kinase isoforms. The 
Pkrl gene encodes the PKL and PKR isoforms, which are expressed in the liver and red blood cells 
respectively. Most tissues express either the PKM1 or PKM2 isoform encoded by the Pkm gene. 
PKM1 is found in many normal differentiated tissues whereas PKM2 is expressed in most 
proliferating cells including all cancer cell lines and tumors tested9. PKM1 and PKM2 are derived 
from alternative splicing of a Pkm gene transcript by mutual exclusion of a single conserved exon 
encoding 56 amino acids10-12. Despite very similar primary sequences, PKM1 and PKM2 have 
different catalytic and regulatory properties. PKM1 exhibits high constitutive enzymatic activity13.  In 
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contrast, PKM2 is less active, but can be allosterically activated by the upstream glycolytic 
metabolite fructose-1,6-bisphosphate (FBP)14. It has been hypothesized that FBP binding induces 
conformational changes that promote the association of the protein into homotetramers that 
comprise the most active form of the enzyme15,16.  
Unlike other pyruvate kinase isoforms, PKM2 can interact with proteins harboring 
phosphorylated tyrosine residues leading to release of FBP which, in turn, reduces the activity of 
the enzyme17. Low PKM2 activity, in conjunction with increased glucose uptake, facilitates the flux 
of glucose carbons into anabolic pathways derived from glycolysis3,9,17,18. Also, PKM2, but not 
PKM1, can be inhibited by direct oxidation of cysteine 358 as an adaptive response to increased 
intracellular reactive oxygen species (ROS)19. Additionally, PKM2 expression in cancer cells is 
associated with enhanced phosphorylation of H11 on phosphoglycerate mutase 1 (PGAM1) by 
PEP20. This pathway provides an alternative route for pyruvate production while bypassing the 
generation of ATP via the pyruvate kinase step and thereby allows glycolysis to proceed at high 
rates21. Replacement of PKM2 with the constitutively active isoform PKM1 results in reduced 
lactate production, enhanced oxygen consumption, and a decrease in PGAM1 phosphorylation8,20. 
Furthermore, there appears to be selection for PKM2 expression for growth in vivo. However, it is 
also possible that PKM2 expression reflects selection against high pyruvate kinase activity and 
therefore against expression of PKM1, raising the possibility that activation of PKM2 may impede 
cancer cell proliferation by interfering with regulatory mechanisms critical for proliferative 
metabolism.  
Recently, we identified small molecules that selectively activate PKM2 over other pyruvate 
kinase isoforms in vitro22,23. Here we show that synthetic PKM2 activators can increase PKM2 
activity in cells to levels that are comparable to PKM1 expression. PKM2 activators bind to a 
pocket at the PKM2 subunit interface and thereby enhance association of PKM2 subunits into 
stable tetramers. Importantly, this mechanism of tetramer stabilization is refractory to inhibition by 
tyrosine-phosphorylated proteins and influences cell metabolism. Among the two classes of PKM2 
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activators described here, a member of the thieno[3,2-b]pyrrole[3,2-d]pyridazinones class, TEPP-
46, has pharmacokinetic properties amenable to experiments in mice. Expression of PKM1 or 
continuous dosing of mice with TEPP-46, decreases development of human cancer cell 
xenografts, suggesting that increased pyruvate kinase activity can impair tumorigenesis. 
 
RESULTS 
Increased pyruvate kinase activity impairs tumor growth 
We have previously demonstrated that replacement of PKM2 with PKM1 impairs the ability 
of H1299 human non-small cell lung cancer cells to form xenograft tumors in mice8. This 
observation may reflect selection for PKM2 expression in tumors. However, because the ability to 
decrease PKM2 activity correlates with increased cell proliferation17, it is also possible that high 
pyruvate kinase activity associated with the expression of the constitutively active PKM1 isoform 
can suppress tumor growth. To address whether PKM1 expression alone affects tumor formation 
in vivo, we engineered H1299 cells to stably express Flag-tagged PKM1 in the presence of 
endogenous PKM2 (henceforth referred to as H1299-PKM1 cells).  Expression of Flag-PKM1 did 
not affect endogenous PKM2 levels (Supplementary Fig. 1a), but resulted in a 35±17% increase 
in total cellular pyruvate kinase activity (Fig. 1a). Both PKM1 and PKM2 can associate into 
tetramers24,25.  To determine if PKM1 can associate with endogenous PKM2 we used an anti-Flag 
antibody to immunoprecipitate Flag-PKM1. SDS-PAGE of the immunoprecipitated protein followed 
by silver staining revealed the presence of stoichiometric amounts of Flag-PKM1 and endogenous 
co-precipitating PKM2 (Supplementary Fig. 1b).  The identity of PKM2 was confirmed by mass 
spectrometry (Supplementary Fig. 1c). These data show that PKM1 can form heterocomplexes 
with endogenous PKM2, and that immunoprecipitation of exogenously expressed Flag-tagged 
pyruvate kinase can be used to assess formation of multimeric pyruvate kinase complexes in cells. 
Furthermore, these data suggest that expression of PKM1 in PKM2-expressing cells suffices to 
increase total pyruvate kinase activity. 
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To determine whether PKM1 expression with enhanced pyruvate kinase activity interferes 
with tumor growth, we compared the ability of H1299-PKM1 versus parental H1299 cells to form 
tumors in immunocompromised (nu/nu) mice. Tumors emerged in all sites where parental cells 
were injected after a median of 31.5 days (Fig. 1b). However, only 4 out of 10 sites injected with 
H1299-PKM1 cells gave rise to tumors. Notably, tumors derived from H1299-PKM1 cells were 
significantly smaller (Fig. 1c), occurred later, and had reduced expression of Flag-PKM1 relative to 
the injected H1299-PKM1 cells (Fig. 1d and Supplementary Fig. 2). Furthermore, pyruvate kinase 
activity in tumor lysates was consistently lower than that seen in parental H1299 cells (Fig. 1e). As 
the same numbers of parental or PKM1-expressing cells were injected to initiate tumors, the low 
pyruvate kinase activity in all tumors suggests that the small tumors derived from H1299-PKM1 
cells arose from a subset of cells that lost PKM1 expression. These data support the notion that 
decreased pyruvate kinase activity is associated with tumor growth, and suggest that high pyruvate 
kinase activity can suppress formation of cancer cell xenograft tumors in mice.  
 
Small molecules can specifically activate PKM2 in cells 
A recent screen identified two structurally distinct classes of small molecule PKM2 
activators22,23. A representative compound from each class was selected for further studies; the 
thieno[3,2-b]pyrrole[3,2-d]pyridazinone NCGC00186528 (TEPP-46; ML265, PubChem CID: 
44246499) and the substituted N,N’-diarylsulfonamide NCGC00185916 (DASA-58; ML203, 
PubChem CID: 44543605) are both potent activators of recombinant PKM2 (TEPP-46: AC90=470 
nM, AC50=92 nM; DASA-58: AC90=680 nM, AC50=38 nM)  (Fig. 2a) and are soluble in aqueous 
solution22,23. Furthermore, TEPP-46 and DASA-58 are selective for PKM2 as they do not activate 
recombinant PKM1 in vitro (Fig. 2b). To investigate whether these compounds are able to activate 
PKM2 selectively in cells, we engineered A549 cells to express Flag-PKM1 or Flag-PKM2 with 
concomitant knock-down of endogenous PKM2 (referred to as A549-PKM1/kd and A549-PKM2/kd, 
respectively) (Fig. 2c, right panel). We treated these cells with 40 µM DASA-58 and assayed 
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pyruvate kinase activity in the corresponding cell lysates. Consistent with our results in H1299 
cells, lysates from DMSO-treated A549-PKM1/kd cells had 233±27% more pyruvate kinase activity 
than A549-PKM2/kd cells. We observed no increase in pyruvate kinase activity following treatment 
of A549-PKM1/kd cells with DASA-58; however DASA-58 treatment resulted in a 248±21% 
increase of pyruvate kinase activity in A549-PKM2/kd cell lysates. These data suggest that DASA-
58 can selectively activate PKM2 in cells.  
In a manner analogous to FBP, both TEPP-46 and DASA-58 decrease the Km of PKM2 for 
PEP with no effect on the Km for ADP22,23, suggesting that TEPP-46 and DASA-58 activate PKM2 
by a mechanism similar to that of the endogenous activator FBP.  To determine whether FBP could 
further activate PKM2 in activator-treated cells, we incubated A549 cells with increasing 
concentrations (0-100 µM) of DASA-58 and assayed PKM2 activity in the corresponding lysates in 
the presence or absence of FBP. In the absence of FBP, DASA-58 activated PKM2 in a dose-
dependent manner with an effective cellular half-activation concentration (EC50) of 19.6 µM (Fig. 
2d). However, in the presence of high physiological levels of FBP (200 µM), we observed no 
significant additional increase in activity as a result of activator treatment. These data are 
consistent with the in vitro kinetic analysis suggesting that DASA-58 enhances PKM2 activity by a 
mechanism similar to FBP.  
 
PKM2 activators stabilize subunit interactions 
The most active form of PKM2 is as a tetramer, and subunit association is thought to be 
promoted by FBP. To test this hypothesis, we separated bacterially expressed recombinant PKM2 
into monomers and tetramers by size exclusion chromatography (Supplementary Fig. 3a) and 
assayed the ability of FBP to increase PKM2 activity. PKM2 tetramers showed greater than 50-fold 
higher activity compared to PKM2 monomers (Supplementary Fig. 3b). Addition of FBP had 
minimal effects on PKM2 tetramer activity (consistent with bacterial FBP being trapped on the 
stable tetramers17), but FBP increased the activity of PKM2 monomers by approximately 70% 
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(Supplementary Fig. 3c). The relatively modest activation of the monomers likely reflects the slow 
kinetics of assembling tetramers from monomers under dilute conditions. To determine if FBP 
activation of monomers is accompanied by changes in PKM2 subunit composition, we performed 
sucrose gradient ultracentrifugation on purified recombinant PKM2. Under these conditions, the 
majority of PKM2 is found to dissociate into monomers (Fig. 3a). Exposure of PKM2 to FBP 
throughout the experiment results in a shift of the protein into a tetrameric configuration that is 
comparable to that seen with the constitutively active PKM1 isoform (Supplementary Fig. 3d). To 
investigate if small molecule activators also promote pyruvate kinase subunit association into 
tetramers, we incubated purified PKM2 with TEPP-46 or DASA-58. We observed only a partial shift 
of PKM2 into tetramers with both activators alone (Supplementary Fig. 3d). As only a fraction of 
bacterially expressed PKM2 is bound to FBP (Supplementary Fig. 3a-c) we reasoned that the 
activators may only stabilize FBP-bound PKM2. Consistent with this hypothesis, transient 
incubation of PKM2 with FBP prior to addition of TEPP-46 resulted in the activator fully stabilizing 
the PKM2 tetramer. Overall, these data suggest that unlike PKM2, PKM1 is a stable tetrameric 
enzyme, and both FBP and small molecule activators increase PKM2 activity by promoting the 
tetrameric state.  
To investigate whether PKM2 activators promote pyruvate kinase subunit association in 
cells, we generated A549 cells stably expressing Flag-PKM1 or Flag-PKM2 and treated them with 
DMSO or DASA-58. Following lysis and immunoprecipitation with Flag antibodies, we determined 
the relative amount of endogenous PKM2 that co-precipitated under the various conditions by 
western blot using an antibody that recognizes an epitope common to both pyruvate kinase 
isoforms. Flag-PKM1 immunoprecipitated equivalent amounts of endogenous PKM2 irrespective of 
activator treatment (Supplementary Fig. 3e). In contrast, DASA-58 treatment resulted in increased 
levels of endogenous PKM2 immunoprecipating with Flag-PKM2 when compared with DMSO-
treated cells or cells treated with an inactive analog of DASA-5823. Similar results were obtained 
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with TEPP-46 (Supplementary Fig. 3f). These data indicate that PKM2 activators can promote 
stable association of PKM2 subunits in cells. 
Phosphotyrosine interaction with PKM2 downstream of growth factor signaling is critical for 
both cell proliferation and metabolic changes that promote anabolism17. Binding to phosphotyrosine 
decreases PKM2 activity by catalyzing release of FBP from the enzyme17,26. Pervanadate inhibits 
tyrosine phosphatases to acutely increase levels of tyrosine-phosphorylated proteins, and 
pervanadate treatment of cells results in inhibition of PKM2 but not inhibition of PKM1 activity17,20. 
To determine whether PKM2 activity inhibition caused by increased tyrosine phosphorylated 
proteins results in destabilization of PKM2 tetramers in cells, we treated cells with pervanadate and 
determined the stoichiometry of PKM2 subunit composition by size exclusion chromatography. In 
logarithmically growing A549 cells, approximately half of the PKM2 elutes as a tetramer while the 
other half dissociates to monomers during size exclusion chromatography (Fig. 3b, upper panels). 
Under these conditions we do not detect a significant population of dimeric PKM2. Pervanadate 
treatment caused disappearance of PKM2 tetramers and the entire PKM2 population was detected 
as monomers in this assay. We then tested whether PKM2 activators influence regulation of PKM2 
tetramerization by tyrosine phosphorylated proteins. In logarithmically growing cells treated with 
TEPP-46 all PKM2 was found as a tetramer (Fig. 3b, third panel). Moreover, PKM2 tetramers were 
preserved even after treatment of cells with pervanadate (Fig. 3b, bottom panel). Similar results 
were obtained with H1299 cells (Supplementary Fig. 3g). 
To test whether PKM2 activators also affect PKM2 activity when levels of tyrosine-
phosphorylated proteins are increased, we assayed PKM2 activity in lysates of cells treated with 
DMSO, TEPP-46 or DASA-58 followed by pervanadate treatment. Pre-treatment of cells with 
TEPP-46 or DASA-58 prevented pervanadate-induced inhibition of PKM2 activity (Fig. 3c). It is 
plausible that activator binding renders PKM2 resistant to an inhibitory modification induced by 
pervanadate treatment. However, a phosphotyrosine-containing peptide corresponding to the 
optimal PKM2 interaction motif17 can promote dissociation of PKM2 tetramers (Supplementary 
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Fig. 3h), but does not inhibit the ability of TEPP-46 to activate recombinant PKM2 
(Supplementary Fig. 3i). These results indicate that activators render PKM2 tetramers resistant to 
dissociation induced by phosphotyrosine signaling.  
Overall, these data argue that PKM2 activators enhance PKM2 activity by promoting the 
stable (active) tetrameric form of PKM2.  However, similar to PKM1 but unlike the endogenous 
activator FBP, small molecule PKM2 activators promote the active form of the enzyme even in the 
presence of increased phosphotyrosine levels that would otherwise lower PKM2 activity.   
 
Structural analysis of PKM2 activator mode of binding 
Based on these biochemical studies, it is possible that these agents activate PKM2 by 
binding at the same site as FBP but fail to be released following interaction with phosphotyrosine. 
Alternatively, PKM2 activators may stabilize the tetramer in another way. To explore these 
possibilities, purified recombinant PKM2 was crystallized in the presence of TEPP-46 or DASA-58. 
Our refined model shows that one tetrameric PKM2 contains two activators and four FBP 
molecules (Supplementary Table 1, Fig. 4a and Supplementary Fig. 4a). The four FBP 
molecules co-purified from the E. coli cells where PKM2 was produced and they were found to 
occupy all four of the FBP binding pockets of the PKM2 tetramer. In comparison, one activator was 
found in the interface (named A-A′) between the A domains of each dimer, approximately 35Å 
away from the FBP binding pocket (Fig. 4a and Supplementary Fig. 4a). The bound activator was 
completely buried within the A-A′ interface. The activator binding pocket was lined with equivalent 
sets of residues provided by each of the PKM2 molecules forming the A-A′ interface, where the 
activator was accommodated through polar and van der Waals interactions with pocket-lining 
residues (Fig. 4b and Supplementary Fig. 4b). Particularly in the case of TEPP-46, 
crystallographic evidence suggests that the binding orientation of the activator alternates based on 
a pseudo-twofold axis that is co-linear with both the nitrogen-methyl carbon bond of the N-methyl 
pyrrole moiety of TEPP-46 and the pseudo-twofold axis of the A-A' interface. The extra space in 
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the pocket was filled with solvent molecules or ions, which also mediate hydrogen bonds between 
the activator and the pocket-lining residues (Fig. 4b). These data show that TEPP-46 and DASA-
58 bind PKM2 through a binding pocket distinct from that of FBP and that they stabilize a 
tetrameric conformational state. 
FBP is thought to contribute to tetramer formation by stabilizing the C-C’ interface. Given 
the distinct location of the activator binding pocket, we investigated whether activator binding 
results in stabilization of subunit interaction along the A-A’ interface. A recent study showed that 
acetylation of K305 results in decreased PKM2 subunit association as another way to inactivate 
the enzyme27. The ε-amino group of K305 interacts via a salt bridge with E384 in the neighboring 
subunit along the A-A’ interface (Supplementary Fig. 4c). Acetylation may interfere with this 
interaction resulting in destabilization of the PKM2 tetramer. We mutated K305 to Q to mimic 
acetylation. Flag-PKM2(K305Q) failed to co-precipitate endogenous PKM2 (Fig. 4c). Given that 
the activator binds between two PKM2 subunits at the A-A’ interface where K305 and E384 reside, 
we asked if PKM2 activator can rescue the interaction between Flag-PKM2(K305Q) and 
endogenous PKM2. Indeed, treatment of cells with DASA-58 restored the ability of Flag-
PKM2(K305Q) to co-precipitate endogenous PKM2 (Fig. 4c). These data further support a model 
where PKM2 activators function by binding at the A-A’ interface and stabilize the PKM2 tetramer, 
and suggest that the activators could circumvent in vivo mechanisms for inhibition of PKM2 activity. 
 
PKM2 activators alter metabolism in cultured cells 
Overall, our results suggest that PKM2 activators will mimic the regulatory properties of 
constitutively active PKM1, thereby promoting high PKM2 activity regardless of the known 
mechanisms cells use to decrease pyruvate kinase activity.  Therefore, we next examined the 
effects of activator treatment on cellular proliferation. Similar to results observed when PKM2 is 
replaced with PKM18, under standard tissue culture conditions PKM2 activators had no significant 
effects on cell proliferation when tested across several lines (Fig. 5a and Supplementary Fig. 5). 
12	  
	  
In contrast, when we assayed proliferation under hypoxic conditions (1% O2), PKM2 activator 
treatment resulted in a decreased rate of cell proliferation compared to DMSO-treated cells (Fig. 
5a). Similarly, expression of PKM1 in the presence of endogenous PKM2 had no effect on cell 
proliferation in standard tissue culture conditions, but inhibited cell proliferation under hypoxia to a 
similar degree as treatment with activators. These observations are consistent with previous data 
showing that replacement of PKM2 with PKM1 also impairs cell proliferation under low oxygen8. 
To test our hypothesis that PKM2 activators mimic a metabolic state found in PKM1-
expressing cells, we interrogated the effects of activator treatment on cell metabolism. 
Replacement of PKM2 with PKM1 in cultured cells results in reduced lactate production and 
enhanced oxygen consumption8. Acute treatment of H1299 cells with DASA-58 also resulted in 
decreased lactate production (Fig. 5b). Unlike cells where PKM2 is replaced with PKM1, 
expression of PKM1 in the presence of endogenous PKM2 or activator treatment had no significant 
effect on oxygen consumption (Supplementary Fig. 6a). Furthermore, DASA-58 treatment did not 
affect glucose or glutamine consumption (Supplementary Fig. 6b-c), indicating that changes in 
uptake of major nutrients are unlikely to underlie the observed metabolic phenotypes. Inhibition of 
PKM2 activity mediated by phosphotyrosine signaling results in more efficient incorporation of 
glucose carbons into lipids17.  To determine if PKM2 activator treatment inhibits glucose carbon 
incorporation into lipids, cells were incubated with [6-14C]-glucose in the presence of DMSO or 
DASA-58, cellular lipids were extracted, and 14C-labelled lipids were quantified by scintillation 
counting. DASA-58 treatment resulted in a significant decrease in glucose-derived carbon 
incorporation into lipids (Fig. 5c, left). Similarly, we observed a decrease in glucose carbon 
incorporation into lipids in H1299-PKM1 cells (Fig. 5c, right). We also used gas chromatography-
mass spectrometry (GC-MS) to analyze metabolite extracts of cells incubated with 13C-labeled 
glucose. DASA-58 treatment resulted in diminished incorporation of glucose carbons into acetyl-
CoA used for de novo palmitate synthesis (Fig. 5d and Supplementary Fig. 6d) and a decrease in 
overall de novo lipogenesis (Fig. 5e). TEPP-46 also induced a decrease in the intracellular levels 
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of acetyl-coA, lactate, ribose phosphate and serine (Fig. 5f-h and Supplementary Fig. 6e). Ribose 
phosphate is a key intermediate for the biosynthesis of nucleotides via the pentose phosphate 
pathway, and serine, in addition to being incorporated directly into proteins can serve as a 
precursor for lipid head groups and glycine as well as provide carbon to the folate pool. Notably, 
these changes, along with overall changes in other intracellular metabolite concentrations 
(Supplementary Fig. 6f), were evident only in parental cells and not PKM1-expressing cells, 
indicating that the effects of the activator on cellular metabolism are specific to PKM2. No 
significant differences in the concentrations of lactate, ribose phosphate or serine were observed 
between PKM1-expressing and parental cells, most likely reflecting that, unlike transient activation 
of PKM2 by small molecules, selection for PKM1 expression in cells may lead to adaptive changes 
in metabolite levels to compensate for the effects of chronic pyruvate kinase activity elevation. 
Regardless, these data indicate that small molecule activation of PKM2 can alter glucose 
metabolism and can decrease the intracellular concentrations of intermediates required for 
biosynthesis. 
Low PKM2 activity is also associated with increased phosphorylation of PGAM1 on the 
catalytic histidine residue (His11)20. To determine if activator treatment decreases PGAM1 
phosphorylation, we treated cells with DMSO or DASA-58, and analyzed the corresponding lysates 
by 2-D SDS-PAGE/isoelectric focusing to resolve PGAM1 species in cells20.  Similar to PKM1-
expressing cells20, we observed a decrease in PGAM1 phosphorylation as a result of activator 
treatment (Supplementary Fig. 7). Together, these data suggest that PKM2 activators induce a 
metabolic state in cells comparable to, but distinct from, that seen with PKM1 expression. 
 
PKM2 activator inhibits xenograft tumor growth  
PKM1 expression impairs the ability of cancer cells to grow in vivo as xenografts. To 
determine whether PKM2 activators also impede xenograft tumor growth, we determined which 
compound was suitable for experiments in mice. Based on in vitro absorption, distribution, 
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metabolism and excretion (ADME) profiling studies, we predicted that TEPP-46 would have 
superior in vivo drug exposure compared to other analogs. To determine appropriate repeated 
drug doses for the mouse experiments, we performed single-dose pharmacokinetic and acute 
pharmacodynamic (PK-PD) studies with TEPP-46. Supplementary Fig. 8 shows mouse plasma 
drug concentration over time after a single intravenous, intraperitoneal, or oral dose. TEPP-46 
exhibits good oral bioavailability with relatively low clearance, long half-life, and good volume of 
distribution - parameters that predict for drug exposure in tumor tissues (Supplementary Table 2). 
Acute oral-dose of TEPP-46 at 150 mg/kg readily achieved maximal PKM2 activation measured in 
A549 xenograft tumors (Supplementary Fig. 9a). To ensure that drug treatment could be carried 
out safely for a multi-day dosing regimen, we also performed a 5-day repeat-dose tolerability study 
in mice and showed that 50 mg/kg twice daily was well-tolerated with no sign of weight loss 
(Supplementary Fig. 9b).  
Because 50 mg/kg twice daily oral dosing of TEPP-46 was well tolerated and led to 
reasonable plasma levels in mice, we tested whether this dose of TEPP-46 could promote PKM2 
tetramerization in xenograft tumors. We treated mice bearing H1299 xenograft tumors with vehicle 
or TEPP-46 and analyzed tumor lysates by size exclusion chromatography. In xenografts from 
vehicle-treated mice, very little PKM2 was found as tetramers (Fig. 6a). In contrast, tumors 
exposed to TEPP-46 harbored exclusively tetrameric PKM2. Metabolomic analysis revealed that, 
similar to the effects observed in cultured cells following treatment with TEPP-46, tumors derived 
from mice treated with TEPP-46 had lower concentrations of lactate, ribose phosphate, and serine 
(Fig. 6b). We then tested whether these changes in PKM2 activity and tumor metabolism impact 
the ability of H1299 cells to form xenografts. H1299 cells were injected into immunocompromised 
(nu/nu) mice and the animals were randomly divided into two cohorts, one treated with vehicle and 
the other treated with 50 mg/kg of TEPP-46, dosed twice daily for the duration of the experiment.  
No apparent toxicity was observed in any mice, despite over 7 weeks of continuous drug exposure 
based on blood counts and serum chemistries (Supplementary Table 3) as well as histological 
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examination of blood, bone marrow, liver, kidney, heart, and the gastrointestinal tract. Tumors in 
activator-treated mice emerged with a delayed latency compared to tumors in vehicle-treated mice 
(Fig. 6c). In addition, the tumors from activator-treated mice were smaller than those arising in 
vehicle-treated animals (Fig. 6d). TEPP-46 was detectable in tumors from activator-treated mice 
suggesting that cells in the tumor were exposed to the drug.  
These data demonstrate that cancer cells in xenograft tumors are exposed to TEPP-46 
after several weeks of oral dosing, and that this can mimic PKM1 expression to impair growth of 
H1299 cells as xenograft tumors.  
 
DISCUSSION 
Cancer cells harbor genetic changes that allow them to increase nutrient uptake and alter 
metabolism to support anabolic processes, and interfering with this metabolic program is a strategy 
for cancer therapy1,2. Altered glucose metabolism in cancer cells is mediated in part by expression 
of PKM2, which has unique regulatory properties. Unlike its splice variant PKM1, which is found in 
many normal tissues, PKM2 is allosterically activated by FBP and can interact with tyrosine-
phosphorylated proteins to release FBP and decrease enzyme activity. Thus, growth factor 
signaling promotes decreased PKM2 activity and availability of glycolytic metabolites for anabolic 
pathways that branch from glycolysis. This suggests that activation of PKM2 might oppose the 
effects of growth signaling and interfere with anabolic glucose metabolism. 
Consistent with this hypothesis, our data show that high pyruvate kinase activity caused by 
PKM1 expression or small molecule PKM2 activation impedes the ability of cancer cells to form 
tumors in mice. PKM1 can associate with endogenous PKM2 and form heterocomplexes that are 
likely insensitive to FBP regulation and thus exhibit higher activity. Recent publications have 
described non-enzymatic functions for PKM228-30.  While these non-classical PKM2 activities may 
also play a role in tumor formation, our data suggest that the ability to decrease enzyme activity is 
also an important property of the enzyme that may drive PKM2 selection in tumors.  Furthermore, 
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these experiments provide evidence that elevated pyruvate kinase activity can be incompatible 
with efficient tumor growth. 
Small molecule PKM2 activators can mimic the enzymatic properties of PKM1 in PKM2-
expressing cells and alter cell metabolism. Our studies focused on DASA-58 and TEPP-46, which 
are representative of two classes of PKM2-activating compounds22,23. These small molecules 
induce changes in the kinetic properties of PKM2 that are identical to those induced by the 
endogenous PKM2 activator FBP, suggesting that PKM2 could adopt a PKM1-like state in cells 
when FBP is high and/or in the absence of phosphotyrosine signaling. Surprisingly, structural 
analyses of the activators bound to PKM2 tetramers revealed a binding pocket at the interface of 
subunit interaction that is distinct from the site of FBP binding. Furthermore, unlike FBP, which 
stabilizes the C-C’ interface of the active tetramer, the small molecule activators stabilize the A-A’ 
interface.  Interestingly, FBP was also observed in the crystals containing small molecule 
activators, and activators stabilize PKM2 tetramers more effectively in the presence of FBP. This 
raises the possibility that FBP binding is still required for small molecule activation and that 
stabilization of the A-A’ interface inhibits FBP release.  Nevertheless, these compounds enhance 
PKM2 enzymatic activity in a manner that renders PKM2 resistant to inhibition by phosphotyrosine 
binding, and interaction with phosphotyrosine is the only mechanism described to release FBP 
from PKM2. No natural ligands have been identified that bind PKM2 in the same site as the PKM2 
activators, but given that multiple activator classes bind in the same pocket, it is possible that this 
represents a previously unknown site of pyruvate kinase regulation. 
Our findings are consistent with PMK2 existing in a monomer-tetramer equilibrium that can 
be altered by the presence of FBP, TEPP-46 or DASA-58.  Although this study agrees with 
previous reports demonstrating that the fully associated tetrameric form of PKM2 is the active form 
of the enzyme, dimeric PKM2 was not a predominant form of the enzyme observed in our assays.  
Previous studies have described PKM2 dimers following isoelectric focusing chromatography9. It is 
possible that the methods we used to assess PKM2 multimeric state favor complete tetramer 
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dissociation to monomers. We suspect that much of the PKM2 in vivo exists in an equilibrium 
between loosely associated tetramers with low activity and tightly associated tetramers exhibiting 
high activity, and that this equilibrium is influenced by FBP levels and phosphotyrosine signaling or 
post-translational modifications that destabilize the loosely-associated (low activity) 
tetramer17,19,26,27. 
PKM2 activators may impair tumor cell proliferation by interfering with anabolic metabolism. 
Activator treatment in vitro and in vivo results in decreased pools of ribose-phosphate and serine, 
which are key precursors for nucleotide, lipid and amino acid metabolism. However, no change in 
metabolite pools were seen when pyruvate kinase activity was elevated by chronic PKM1 
expression in vitro, suggesting that the metabolic states elicited by these two treatments may not 
be equivalent. It is possible that this response to PKM1 expression may reflect adaptive events that 
can more effectively compensate for increased pyruvate kinase activity in vitro. PKM2 activator 
treatment also reduced incorporation of glucose carbons into lactate and lipids, thus interfering with 
the increased lactate production used by many tumors to establish a redox balance compatible 
with high glycolytic rates3. Lipids are essential components of new cells and reduced lipid 
production has been shown to inhibit proliferation31. Interestingly, the effects of PKM2 activation on 
proliferation in cell culture are only evident under hypoxic conditions, suggesting that glucose-
dependent anabolic pathways may only be important for proliferation under some conditions. 
Oxidation-induced inhibition of PKM2 under hypoxia may support NADPH production via the 
oxidative branch of the pentose phosphate pathway to sustain antioxidant responses19. While the 
source of NADPH for biosynthetic processes, including lipid synthesis, remains a subject of active 
investigation, the ability of PKM2 to control cellular redox state may partly underlie the selective 
effects of PKM2 activation on proliferation under hypoxia. 
While our data indicate that small molecule activation of PKM2 can impede the proliferation 
of cancer cells in xenograft models, it remains to be determined whether such compounds will be 
similarly effective in autochthonous mouse tumor models or be efficacious as a cancer therapy in 
18	  
	  
humans. PKM2 activators can also sensitize cells to oxidative stress-induced death raising the 
possibility that such compounds could enhance tumor killing in combination with drugs that 
increase cellular ROS6,19. Regardless, this study further supports the notion that pyruvate kinase 
acts as an important regulatory node in glycolysis to control glucose fate in cells and argues that 
high pyruvate kinase activity is not conducive to the anabolic metabolism necessary for tumor 
growth.   
 
MATERIALS AND METHODS 
All mouse studies were performed in accordance with institutional guidelines and approved by the 
MIT committee on animal care.  Full methods are included in the supplementary information. 
Cell culture 
293T and A549 cells were cultured in standard DMEM-based media, and H1299, T.T, SN12C, and 
SKMel28 cells were cultured in RPMI-based media. For all hypoxia experiments the media were 
supplemented with 20 mM HEPES. Cells expressing specific Flag-tagged isoforms of mouse 
pyruvate kinase M, or mutants thereof, in the absence of endogenous PKM2 were derived as 
described8.  To measure doubling time, 20,000 cells were seeded in 12-well plates and, at days 0, 
2, 4 and 6, cells were fixed with 10% formalin and stained with 0.1% w/v crystal violet in 20% 
methanol.  Stained plates were dried and cell-bound crystal violet was solubilized in 10% acetic 
acid for measurement of cell mass by crystal violet absorbance at 595 nm.  For cell viability, 2,000 
cells were seeded in 96-well plates and analyzed using CellTiter96® AQueous (Promega) or MTS (3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay 
(Promega) according to the manufacturer’s instructions. 
Western blot 
Cell or tissue lysates were analyzed by SDS-PAGE and western blot using standard 
protocols and the following primary antibodies: anti-pyruvate kinase (Abcam, ab6191), anti-PKM1 
(Sigma, SAB4200094), anti-PKM2 (Cell Signaling, 4053), anti-FLAG (Sigma, F3165), and anti-
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actin (Abcam, ab1801). Where indicated Flag-agarose (Sigma-A2220) was used for 
immunoprecipitation of Flag-tagged proteins.  Iso-electric focusing/SDS-PAGE two-dimensional 
Western blot analysis was performed as described previously20. 
Xenograft experiments 
H1299 cells with and without constitutive expression of mouse PKM1 were suspended in 
sterile PBS, and 5x106 cells were injected subcutaneously into nu/nu mice.  Tumor growth was 
monitored, mice sacrificed after the time indicated, and tumors were harvested for analysis. 
PKM2 activity  
Pyruvate kinase activity was measured as described previously32. Where indicated, 100 µM 
pervanadate was added 10 minutes prior to cell lysis.  For the phosphotyrosine peptide 
experiments, the amino acid sequences of the peptides were: GGAVDDDYAQFANGG (M2tide) 
and  GGAVDDDpYAQFANGG (P-M2tide)17. 
Sucrose-gradient ultracentrifugation 
Recombinant PKM2 was incubated with 500 nM TEPP-46, 1 µM DASA-58, or 100 µM FBP 
for 30 minutes on ice before layering on a 10-40% sucrose gradient.  For conditions involving FBP, 
100 µM FBP was included in the sucrose gradient except where indicated that PKM2 was 
transiently exposed to FBP.  Gradients were spun at 55,000 rpm for 10 hours using a Beckman 
TLS-55 rotor and fractions analyzed by SDS-PAGE or Coomassie blue staining.  Coomassie blue 
staining intensity was quantified using IR fluorescence. 
Size exclusion chromatography 
Recombinant protein or ~2 mg of cellular protein was separated on a HiPrep 16/60 
Sephacryl S-200 HR column (GE) in 50 mM sodium phosphate, 150 mM sodium chloride, pH 7.2.  
Fractions were analyzed by UV absorbance or SDS-PAGE and western blot as indicated. 
Recombinant PKM2 
Full-length human PKM2 was expressed as a His-tagged fusion protein in Escherichia coli 
strain BL21(DE3) and isolated by Ni-NTA affinity chromatography.  For structural studies 
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recombinant PKM2 was further purified by size exclusion chromatography. The final protein purity 
was confirmed by SDS-PAGE. Further details are provided in the Supplementary Methods. 
Protein crystallization and structure determination 
For co-crystallization, PKM2 was incubated overnight at room temperature in the presence 
of 5 mM activators (TEPP-46 or DASA-58) and crystallization trays were set up using the sitting-
drop vapor diffusion method with droplets of protein solution (0.5 µl) and reservoir solution (0.5 µl). 
The best diffracting crystals were obtained from a reservoir solution containing 25% P3350, 0.2 M 
NH4OAc and 0.1 M Bis-Tris pH 6.5. Crystals were cryo-protected with 50% Paratone-N, 50% 
mineral oil for freezing them directly in liquid nitrogen for x-ray data collection. Data collection was 
carried out at the Advanced Photon Source beamline 23ID-B. For each complex crystal, 360 0.5° 
oscillation images were collected in a continuous sweep. Data were reduced with HKL-200033 
(DASA-58) or HKL-300034 (TEPP-46). Crystals belonged to space group P21. Structures were 
solved by direct replacement with the isomorphous Protein Data Bank (PDB)35 entry 3GQY. 
Activator geometry restraints were obtained at the PRODRG36 server. Iterations of model 
rebuilding, refinement and geometry validation were performed with COOT37, REFMAC38 and 
MOLPROBITY39, respectively. 
Protein identification by LC-MS/MS 
Pyruvate kinase immunoprecipitates were separated by SDS-PAGE and the band 
corresponding to pyruvate kinase by molecular weight excised. The samples were subjected to in-
gel trypsin digestion and analyzed by reversed-phase microcapillary/tandem mass spectrometry 
(LC/MS/MS) using an EASY-nLC splitless nanoflow HPLC (Thermo Fisher Scientific) with a self-
packed 75 µm id x 15 cm C18 Picofrit column (New Objective) coupled to a LTQ-Orbitrap XL mass 
spectrometer (Thermo Scientific). Data was collected in positive ion mode at 300 nL/min with one 
full MS-FT scan followed by six MS/MS-IT scans via collision induced dissociation (CID). MS/MS 
spectra were searched against the concatenated target and decoy (reversed) Swiss-Prot protein 
database using Sequest (Proteomics Browser Software (PBS), Thermo Fisher Scientific). Peptides 
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passing a false discovery rate (FDR) threshold of 1% were accepted. Additional details are 
provided in the Supplementary Methods. 
Metabolism measurements 
Glucose-dependent lipid synthesis was performed as described previously31. Lactate levels 
were measured using YSI 7100 Select Biochemistry Analyzer (YSI Incorporated).  Oxygen 
consumption rates were measured using a polarographic oxygen electrode40.  Where indicated 
metabolites and lipid synthesis were measured using GC-MS.  For determination of [U-
13C6]glucose enrichment in lipogenic AcCoA, A549 cells were cultured for 3 days in the presence of 
tracer and relevant metabolites wer e extracted using methanol and chloroform.  Fatty acid methyl 
esters were generated from lipid biomass by dissolving dried chloroform fractions in 50 µl of 
Methyl-8 reagent (Pierce) and incubating at 60°C for 1 hour. GC/MS analysis was performed using 
an Agilent 6890 GC equipped with a 30m DB-35MS capillary column connected to an Agilent 
5975B MS operating under electron impact (EI) ionization at 70 eV.  Mass isotopomer distributions 
(MIDs) were determined by integrating palmitate ion fragments in the m/z range of 270 to 286. 
Computational estimation of AcCoA enrichment and fractional new palmitate synthesis was 
accomplished as previously described41.  For metabolite measurement by LC-MS/MS42, cells or 
snap-frozen xenograft tumor tissue were extracted with 4:1 v/v MeOH/H2O equilibrated at -80 oC, 
and the extracts were dried under nitrogen gas. Samples were re-suspended in water and 
analyzed using a 5500 QTRAP triple quadrupole mass spectrometer (AB/SCIEX) coupled to a 
Prominence UFLC system (Shimadzu) via selected reaction monitoring (SRM) of metabolites in 
both positive and negative ion mode. ESI voltage was +4900V in positive ion mode and –4500V in 
negative ion mode via positive/negative polarity switching. The dwell time was 3 ms per SRM 
transition and the total cycle time was 1.57 seconds. Peak areas from the total ion current (TIC) for 
each metabolite SRM transition were integrated using MultiQuant v2.0 software (AB/SCIEX). 
Integrated TIC areas corresponding to metabolite concentrations were imported into 
Metaboanalyst43 software, subjected to quantile normalization and statistical significance of 
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changes in metabolite concentrations determined by ANOVA.  Additional details for all metabolism 
measurements are provided in the Supplementary Methods. 
ADME and PK/PD methods 
Pharmacokinetic studies were performed in fasted male BALB/c mice.  TEPP-46 was formulated 
as 40% beta-hydroxy cyclodextrin in water (for IV, IP) or 0.5% carboxy methyl cellulose (400-1000 
cps) with 0.1 % v/v Tween 80 (for PO).  For intravenous administration, TEPP-46 was administered 
as bolus injection at 1 mg/kg dose via tail vein. For intraperitoneal route, TEPP-46 was 
administered with a dosing volume of 10 ml/kg.  For oral dosing, the test compound was 
administered as uniform suspension at 10 mg/kg dose via stomach intubation  Plasma samples 
were collected at the indicated time points and TEPP-46 levels were analyzed by LC-MS/MS with 
lowest level of quantitation  = 0.636 ng/mL. Pharmacokinetics parameters (Cmax, Tmax, T½, AUC) 
were calculated using non-compartmental model with WinNonlin Ver 5.2 statistics software 
(Pharsight Corporation, California, USA).  
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FIGURE LEGENDS 
 
 
Figure 1 | PKM1 expression in cancer cells impairs xenograft tumor growth. (a) H1299 
human lung cancer cells were infected with a retrovirus to stably express Flag-PKM1 (referred to 
as H1299-PKM1 cells in the text) or empty vector (Parental) and after selection, cells were lysed 
and pyruvate kinase activity in the lysates was assayed. (b) Tumor formation over time of parental 
or H1299-PKM1 cells generated as in (a) and injected subcutaneously at equal numbers in nu/nu 
mice [p value calculated by logrank (Mantel-Cox) test]. (c) Final tumor weights from the experiment 
in (b). Mean tumor weights ± s.e.m. are shown and p value was calculated by unpaired Student’s t-
test. (d) Expression of Flag-PKM1 and endogenous PKM2 in the cells used in (b) and (c) was 
determined by western blot with isoform-specific antibodies. Uncropped blots are shown in 
Supplementary Fig. 10. (e) Pyruvate kinase activity assays in lysates of the tumors shown in (d) 
(N=3, 1-way ANOVA and Tukey’s post-test). 
 
Figure 2 | TEPP-46 and DASA-58 isoform specificity in vitro and in cells. (a) Structures of the 
PKM2 activators TEPP-46 and DASA-58 used in this study (b) Purified recombinant human PKM1 
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or PKM2 expressed in bacteria were subjected to pyruvate kinase activity assays in the presence 
of increasing concentrations of TEPP-46 or DASA-58. (c) A549 cells were engineered to stably 
express Flag-PKM1 or Flag-PKM2 in the absence of endogenous PKM2 which was knocked down 
by shRNA. As the PKM1 and PKM2 cDNAs correspond to the mouse orthologues, their expression 
was resistant to knock-down8. Expression of Flag-PKM1 and Flag-PKM2 was confirmed by 
western blot with isoform-specific antibodies (right panel). These cell lines were then treated with 
40 µM DASA-58 for 3 hours and the respective lysates were assayed for pyruvate kinase activity 
(N=3, Student’s t-test). Similar results were observed in H1299 cells (not shown). Uncropped blots 
are shown in Supplementary Fig. 10. (d) A549 cells were treated with the indicated doses of 
DASA-58 for 3 hours, lysed and assayed for pyruvate kinase activity in the presence or absence of 
200 µM FBP. 
 
Figure 3 | Activators promote PKM2 tetramer formation and prevent inhibition by pTyr 
signaling. (a) Sucrose gradient ultracentrifugation profiles of purified recombinant PKM2 and 
effects of FBP and TEPP-46 on PKM2 subunit stoichiometry. Recombinant PKM2 was transiently 
exposed to FBP prior to addition of TEPP-46.  After centrifugation, fractions were collected, 
analyzed by SDS-PAGE and stained with Coomassie Blue. Relative protein amounts were 
calculated by band densitometry on a LiCOR Odyssey infrared imaging system. (b) A549 cells 
were treated with 100 µM pervanadate for 10 min. in the presence or absence of TEPP-46, lysed 
hypotonically, and were analyzed by size exclusion chromatography. Chromatographic fractions 
were then subjected to western blotting with a pyruvate kinase antibody to assess the 
stoichiometry of PKM2 subunit association under these conditions. Uncropped blots are shown in 
Supplementary Fig. 10. (c) Pyruvate kinase activity assays in A549 cells treated with pervanadate 
as in (b) in the presence of DMSO, 1 µM TEPP-46 or 1 µM DASA-58 (N=3, p=0.0044 by 2-way 
ANOVA). 
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Figure 4 | Structural analysis of PKM2 activator mode of action. (a) Interaction between 
tetrameric PKM2 and TEPP-46. The four PKM2 monomers are represented in cartoon mode with 
different colors, respectively. The bound FBP and the activator molecules are colored black and 
red, respectively, and shown as space-filling models. The interfaces between two monomers are 
indicated by dotted lines. (b) Interaction between TEPP-46 and surrounding residues. The bound 
activator is colored yellow and represented by ball and stick model. The residues involved in the 
interaction from two monomers are labeled and colored green and cyan, respectively. The 
hydrogen bonds are indicated by blue dotted lines with distance (Å). (c) DASA-58 stabilizes the 
interaction of Flag-PKM2(K305Q) with endogenous PKM2. Flag-PKM2(K305Q) stably expressed in 
A549 cells was immunoprecipitated from corresponding lysates and the levels of co-precipitating  
endogenous PKM2 were assessed by western blotting with a PKM2 antibody. Uncropped blots are 
shown in Supplementary Fig. 10. 
 
Figure 5 | Metabolic effects of cell treatment with PKM2 activators. (a) Effects of TEPP-46, 
DASA-58 (both used at 30 µM), or PKM1 expression on the doubling time of H1299 cells under 
normoxia (21% O2) or hypoxia (1% O2). (b) Effects of DASA-58 on lactate production from glucose. 
Logarithmically growing H1299 cells were washed with Krebs buffer and incubated in Krebs buffer 
containing glucose in the presence of 50 µM DASA-58 (N=3, Student’s t-test). Produced lactate in 
the incubation medium was assayed after 20 min. as described in materials and methods. (c) 
Logarithmically growing H1299 cells (left), or parental H1299 and H1299-PKM1 cells (right) were 
incubated for 2 hours with 4 µCi/ml [6-14C]-glucose in the presence of DMSO or 30 µM DASA-58, 
cellular lipids were extracted and lipid-incorporated 14C was quantified by scintillation counting. (d) 
Contribution of [U-13C6]glucose to the lipogenic AcCoA pool, and fractional new synthesis of 
palmitate (e) were determined by isotopomer spectral analysis in A549 cells treated with DMSO or 
100 µM DASA-58.  Error bars indicate 95% confidence intervals. (f-h) Intracellular concentrations 
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of lactate, ribose phosphate and serine in parental H1299 or H1299-PKM1 cells treated with 
DMSO or 25 µM of TEPP-46 for 36 hours were determined by targeted LC-MS/MS. 
 
Figure 6 | PKM2 activators impair xenograft growth. (a) Mice bearing H1299 xenograft tumors 
received bolus doses of TEPP-46 at 50 mg/kg 16 hours and 4 hours before sacrifice. Tumors were 
dissected and PKM2 complex stoichiometry in tumor lysates was determined by size exclusion 
chromatography. Uncropped blots are shown in Supplementary Fig. 10. (b) Concentrations of 
lactate, ribose phosphate and serine in H1299 xenograft tumors from mice treated with vehicle or 
TEPP-46 as in (a). (c) H1299 cells were injected subcutaneously into nu/nu mice which were 
subsequently randomly divided into two cohorts, one given vehicle and the other TEPP-46 at 50 
mg/kg twice-daily throughout the duration of the experiment. Injection sites were monitored for 
tumor emergence [p value calculated by logrank (Mantel-Cox) test]. After 52 days, the tumors were 
dissected and final tumor weights were measured (d). Mean tumor weights ± s.e.m. are shown and 
p value was calculated by unpaired Student’s t-test. 
 






